NUCLEO
The first agentic platform for oncology
San Francisco, United States · Founded 2025
- Headquarters
- San Francisco, California
- Employees
- 1–10
- Founded
- 2025
- Business Model
- B2B
- Website
- nucleoresearch.com
- Last Round
- Pre-SeedOct 2025
- Rounds
- 1
About
Nucleo builds AI agents that extract oncological metrics from CT scans—including sarcopenia detection, body composition, and lesion classification—enabling 2,500x faster segmentation than manual workflows. Working with Stanford Hospital, Cedars-Sinai, UCI Health, and Weill Cornell, Nucleo aims to compress the cancer diagnostic interval from 9–11 weeks to under 10 days.
Summary
NUCLEO is an Artificial Intelligence company based in San Francisco, United States, founded in 2025. Its most recent funding was a Pre-Seed round in Oct 2025. Investors include Y Combinator Continuity Fund.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Oct 2025
Investors
Similar Companies
OpenAI is an AI research and deployment company dedicated to ensuring that general-purpose artifi...
Databricks is the pioneer of the data lakehouse, a unified platform for data science, machine lea...
AI-powered platform designed for immigration law firms
AI-powered customer experience and contact center platform serving enterprises globally.
Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...
Palantir Technologies builds data integration and analytics platforms (Gotham and Foundry) for go...